ADC Therapeutics (ADCT) Stock Forecast, Price & News

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ADC Therapeutics in the last year. There are currently 1 sell rating, 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ADCT shares.
View ADCT analyst ratings or view top-rated stocks.

6 brokers have issued twelve-month price targets for ADC Therapeutics' stock. Their ADCT share price forecasts range from $5.00 to $20.00. On average, they expect the company's share price to reach $10.17 in the next year. This suggests a possible upside of 327.2% from the stock's current price.
View analysts price targets for ADCT or view top-rated stocks among Wall Street analysts.

ADC Therapeutics' stock was trading at $3.84 at the start of the year. Since then, ADCT shares have decreased by 38.0% and is now trading at $2.38.
View the best growth stocks for 2023 here.

ADC Therapeutics saw a decline in short interest in the month of May. As of May 15th, there was short interest totaling 6,160,000 shares, a decline of 17.1% from the April 30th total of 7,430,000 shares. Based on an average daily trading volume, of 611,200 shares, the days-to-cover ratio is currently 10.1 days. Approximately 9.8% of the company's shares are short sold.
View ADC Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our ADCT earnings forecast.

ADC Therapeutics SA (NYSE:ADCT) released its earnings results on Tuesday, November, 2nd. The company reported ($0.93) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.92) by $0.01. The company had revenue of $13.15 million for the quarter, compared to analyst estimates of $7.74 million. ADC Therapeutics had a negative trailing twelve-month return on equity of 229.20% and a negative net margin of 108.86%. During the same period last year, the company posted ($0.29) earnings per share.

Based on aggregate information from My MarketBeat watchlists, some companies that other ADC Therapeutics investors own include CVS Health (CVS), Raytheon Technologies (RTX), Home Depot (HD), Procter & Gamble (PG), Thermo Fisher Scientific (TMO), Alibaba Group (BABA), Cisco Systems (CSCO), Johnson & Johnson (JNJ) and CSX (CSX).

(ADCT) raised $126 million in an initial public offering (IPO) on Friday, May 15th 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, BofA Securities and Cowen and Company acted as the underwriters for the IPO.

ADC Therapeutics trades on the New York Stock Exchange (NYSE) under the ticker symbol "ADCT."

ADC Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Prosight Management LP (4.24%), JPMorgan Chase & Co. (4.03%), Sio Capital Management LLC (2.81%), Bank of America Corp DE (2.14%), Perceptive Advisors LLC (1.95%) and Pictet Asset Management SA (1.78%).

Shares of ADCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ADCT stock can currently be purchased for approximately $2.38.

ADC Therapeutics (NYSE:ADCT) has a market capitalization of $182.81 million and generates $209.91 million in revenue each year. The company earns $-155,800,000.00 in net income (profit) each year or ($2.53) on an earnings per share basis.

The company employs 312 workers across the globe.

The official website for the company is www.adctherapeutics.com. The company can be reached via phone at 41-21-653-0200 or via email at amanda.hamilton@adctherapeutics.com.